首页> 外文期刊>International journal of occupational medicine and environmental health. >Characteristics of psychiatric inpatients diagnosed with mental and behavioral disorders caused by psychoactive substances (F11-19 block), with a focus on NPS and psychiatric co-morbidities
【24h】

Characteristics of psychiatric inpatients diagnosed with mental and behavioral disorders caused by psychoactive substances (F11-19 block), with a focus on NPS and psychiatric co-morbidities

机译:精神病物质(F11-19块)诊断患有精神和行为障碍患者的精神病院性的特征,专注于NPS和精神病病理

获取原文
           

摘要

Objectives: This study analyzed the prevalence of new psychoactive substance (NPS) use in the analyzed group and compared demographic features and psychoactive substance profiles between the 2 subgroups (NPS users, non-NPS users). The secondary measure was used to determine the prevalence of psychiatric comorbidities in study group and to compare demographic features and psychoactive substance profiles between 2 subgroups (the F11–19 only diagnosed group and the F11–19 group with psychiatric comorbidities according to ICD-10). Material and Methods: A 12-month retrospective cross-sectional analysis of medical records compiled for adult psychiatric patients who had been admitted to the Regional Psychiatric Hospital in Olsztyn, Poland, in October 1, 2016 – September 30, 2017 was conducted. After analyzing the available medical records, 157 cases were included and analyzed. Data for the study were collected in a specially designed monitoring card from discharge reports, including data from psychiatric examinations, especially anamnesis. Results: The most commonly declared psychoactive substances were amphetamine (AMF) – 54% and cannabinoids – 46%. The prevalence of NPS use in the study group was 34%. Inpatients taking NPS, as compared with non-NPS users, were younger and more often admitted to hospital through the Emergency Department. It was also found that NPS users more often took AMF or cannabinoids, and less frequently benzodiazepines (BDZ) or opioids. However, the taking of AMF, cannabinoids and BDZ was also age-dependent. Conclusions: The prevalence of psychiatric comorbidities in the study group was 9%. Inpatients with psychiatric comorbidities were older and took BDZ significantly more often than AMF. In addition, NPS use affects different groups, including a specific group as the analyzed sample, which shows a similar NPS use profile as different groups described in the literature.
机译:目的:本研究分析了在分析的组中使用新的精神活性物质(NPS)的流行,并在2个子组(NPS用户,非NPS用户)之间的比较人口特征和精神活性物质谱。二次措施用于确定研究组精神病患者的患病率,并在2个亚组(F11-19仅诊断的组和F11-19群中,根据ICD-10对诊断的群体和F11-19组进行比较) 。材料和方法:2016年10月1日,2016年10月1日,为成人精神病患者编制的成人精神病患者均编制的医疗记录的横截面分析为2016年10月1日。在分析可用的医疗记录后,包括157例并分析。该研究的数据被收集在特殊设计的监测卡中,从排放报告,包括精神病检查,特别是厌氧的数据。结果:最常见的精神活性物质是amphetamine(AMF) - 54%和大麻素 - 46%。研究组NPS使用的患病率为34%。与非NPS用户相比,住院患者与非NPS用户相比,通过急诊部门更年轻,更常见于医院。还发现,NPS用户更常常服用AMF或大麻素,且苯二氮卓类(BDZ)或阿片类药物。然而,服用amf,大麻素和bdz也是依赖的。结论:研究组精神病患者的患病率为9%。具有精神病学合并症的住院患者年龄较大,并比AMF更频繁地服用BDZ。此外,NPS使用会影响不同的组,包括特定组作为分析的样品,其显示了与文献中描述的不同组的类似NPS使用简档。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号